ArticleAsian Pacific journal of cancer prevention : APJCP2024
In Silico and In Vitro Study of mRNA Biomarkers for Glioblastoma Multiforme Resistance to Temozolomide (TMZ): The Association with Stemness.
Article in Asian Pacific journal of cancer prevention : APJCP, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioblastoma multiforme (GBM) is an aggressive brain tumor that primarily affects adults. The Stupp Protocol, which includes surgical resection, chemoradiation, and monotherapy with temozolomide (TMZ), is the standard treatment regimen for GBM. However, repeated use of TMZ leads to resistance in GBM cells, resulting in a poor prognosis for patients. This resistance is driven by several intrinsic factors. This study aims to identify potential biomarkers of resistance associated with stemness.
methodsWe utilized datasets from GEO, performed Venn diagram intersection analysis, conducted GO enrichment analysis using DAVID and ENRICHR, carried out pathway enrichment analysis with KEGG and REACTOME, and executed survival analysis with GEPIA. Additionally, we compared mRNA expression using the Human Protein Atlas and validated our findings with qRT-PCR.
resultsWe identified that PAQR6 and ITPKB mRNA expression was consistently higher in TMZ-resistant T98G cells, but TGFBI mRNA expression was found to be significantly higher in TMZ-resistant T98G cells compared to U87MG cells. In addition, a significantly higher CD133 mRNA expression as a stemness marker was found in T98G cells compared to U87MG cells. It is hoped that the acquired disease-related resistance biomarker candidates will be able to be used at the clinical level in terms of non-invasive early detection in GBM patients. However, additional research is required to validate the findings of this preliminary biomarker discovery study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.